Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial

European Urology

Volumn 68, Issue 3, 2015, Pages 354-360

  Arnsrud Godtman, Rebecka ^a   Holmberg, Erik ^a   Lilja, Hans ^b,c,d   Stranne, Johan ^e   Hugosson, Jonas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Opportunistic; Organized; Overdiagnosis; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ERROR; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC PROSTATE SPECIFIC ANTIGEN SCREENING; ORGANIZED PROSTATE SPECIFIC ANTIGEN SCREENING; OVERDIAGNOSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; BIOPSY; BLOOD; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; HEALTH SERVICE; INCIDENCE; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; SWEDEN;

AGED; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; KALLIKREINS; LONGITUDINAL STUDIES; MALE; MEDICAL OVERUSE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SWEDEN;

EID: 84940607673     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.12.006     Document Type: Article

References (31)

1. J. Hugosson, S. Carlsson, G. Aus, and et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
2. F.H. Schroder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
3. P. Nieminen, M. Kallio, A. Anttila, and M. Hakama Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study Int J Cancer 83 1999 55 58
4. K. Bihrmann, A. Jensen, A.H. Olsen, and et al. Performance of systematic and non-systematic ('opportunistic') screening mammography: a comparative study from Denmark J Med Screen 15 2008 23 26
5. R. de Gelder, J.L. Bulliard, C. de Wolf, and et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland Eur J Cancer 45 2009 127 138
6. Council of the European Union. Council recommendation of 2 December 2003 on cancer screening Off J Eur Union L327 2003 34 38
7. G.G. D'Ambrosio, S. Campo, M. Cancian, S. Pecchioli, and G. Mazzaglia Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database Eur J Cancer Prev 19 2010 413 416
8. G.L. Andriole, E.D. Crawford, R.L. Grubb III, and et al. Mortality results from a randomized prostate-cancer screening trial N Engl J Med. 360 2009 1310 1319
9. T. Nordstrom, M. Aly, M.S. Clements, C.E. Weibull, J. Adolfsson, and H. Gronberg Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011 Eur Urol 63 2013 419 425
10. H. Jonsson, B. Holmstrom, S.W. Duffy, and P. Stattin Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden Int J Cancer 129 2011 1881 1888
11. F. Bray, J. Lortet-Tieulent, J. Ferlay, D. Forman, and A. Auvinen Prostate cancer incidence and mortality trends in 37 European countries: an overview Eur J Cancer 46 2010 3040 3052
12. M.M. Center, A. Jemal, J. Lortet-Tieulent, and et al. International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
13. L. Barlow, K. Westergren, L. Holmberg, and M. Talback The completeness of the Swedish Cancer Register: a sample survey for year 1998 Acta Oncol 48 2009 27 33
14. R. Godtman, E. Holmberg, J. Stranne, and J. Hugosson High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm Scand J Urol Nephrol 45 2011 226 232
15. F. Ederer, L.M. Axtell, and S.J. Cutler The relative survival rate: a statistical methodology Natl Cancer Inst Monogr 6 1961 101 121
16. M. Greenwood The errors of sampling of the survivorship table. Reports on public health and medical subjects Vol. 33 1926 HM Stationery Office London
17. R.A. Godtman, E. Holmberg, A. Khatami, J. Stranne, and J. Hugosson Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial Eur Urol 63 2013 101 107
18. D.G. Altman, and P.K. Andersen Calculating the number needed to treat for trials where the outcome is time to an event BMJ 319 1999 1492 1495
19. P. Stattin, S. Carlsson, B. Holmstrom, and et al. Prostate cancer mortality in areas with high and low prostate cancer incidence J Natl Cancer Inst 106 2014 dju007
20. M.J. Roobol, R. Kranse, C.H. Bangma, and et al. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer Eur Urol 64 2013 530 539
21. T.P. Kilpelainen, T.L. Tammela, N. Malila, and et al. Prostate cancer mortality in the Finnish randomized screening trial J Natl Cancer Inst 105 2013 719 725
22. G.L. Andriole, E.D. Crawford, R.L. Grubb III, and et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125 132
23. R.L. Grubb III, P.F. Pinsky, R.T. Greenlee, and et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial BJU Int 102 2008 1524 1530
24. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
25. R. Etzioni, A. Tsodikov, A. Mariotto, and et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19 2008 175 181
26. O. Akre, H. Garmo, J. Adolfsson, M. Lambe, O. Bratt, and P. Stattin Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden Eur Urol 60 2011 554 563
27. W.T. Lowrance, E.B. Elkin, D.S. Yee, and et al. Locally advanced prostate cancer: a population-based study of treatment patterns BJU Int 109 2012 1309 1314
28. G. Lu-Yao, P.C. Albertsen, J.L. Stanford, T.A. Stukel, E.S. Walker-Corkery, and M.J. Barry Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ 325 2002 740
29. G. Lu-Yao, P.C. Albertsen, J.L. Stanford, T.A. Stukel, E. Walker-Corkery, and M.J. Barry Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up J Gen Intern Med 23 2008 1809 1814
30. Swedish National Prostate Cancer Register. Annual report 2012 (in Swedish). http://npcr.se/wp-content/uploads/2013/04/20131121-NPCR-Rapport-2012.pdf.
31. S.J. Otto, I.W. van der Cruijsen, M.K. Liem, and et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Int J Cancer 105 2003 394 399